D0201 - Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents With EoE

Evan Dellon, MD, MPH¹, Mirna Chehade, MD, MPH², Robert M. Genta, MD³, David A. Leiman, MD⁴, Kathryn A. Peterson, MD, MSCI⁵, Jonathan Spergel, MD, PhD⁶, Joshua Wechsler, MD, MS⁷, Enoch Bortey, PhD⁸, Alan T. Chang, BS⁸, Ikuo Hirano, MD, PhD^9
1University of North Carolina School of Medicine, Chapel Hill, NC; ²Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY; ³Baylor College of Medicine, Houston, TX; ⁴Duke University School of Medicine, Durham, NC; ⁵University of Utah, Salt Lake City, UT; ⁶Children’s Hospital of Pennsylvania, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA; ⁷Ann & Robert H. Lurie Children’s Hospital, Chicago, IL; ⁸Allakos Inc., San Carlos, CA; ⁹Northwestern University Feinberg School of Medicine, Chicago, IL

Introduction: Eosinophilic esophagitis (EoE) is a chronic disorder characterized by an inflammatory infiltrate of eosinophils (eos) and mast cells and associated esophageal dysfunction, structural tissue damage, and remodeling. Lirentelimab (LIR, AK002) is a humanized IgG1 mAb directed against Siglec-8, which is expressed selectively on the surface of mature eos and mast cells. The aim of this randomized, double-blind, placebo-controlled phase 2/3 clinical trial was to evaluate the safety and efficacy of LIR in adults and adolescents with active EoE (KRYPTOS, NCT04322708).

Methods: Patients ≥12 years old with symptoms of dysphagia and ≥15 eos/hpf on esophageal biopsy were randomized 1:1:1 to high dose LIR (1 mg/kg x 1 dose then 3 mg/kg x 5 doses [HD]), low dose LIR (1 mg/kg, [LD]) or placebo (PBO) for 6 monthly infusions. Co-primary endpoints were histologic response (defined as the proportion of patients who achieved a peak eos count of ≤6 eos/hpf) at week 24 (W24) and mean absolute change in the daily Dysphagia Symptom Questionnaire (DSQ) score from baseline to weeks 23-24. EGD with esophageal biopsies was performed at screening and at W24.

Results: Of the 276 patients who completed the study, 51 were adolescents (12-17 ys) who had a higher proportion of atopic diseases, peripheral blood eos, serum IgE levels, and prior EoE treatment (Table). In the overall cohort, the histologic co-primary endpoint was met by 88% HD and 92% LD vs. 11% PBO (P < 0.0001; Fig. A1). For adolescents, 94% HD and 94% LD met this compared to 6% PBO (Fig. A2). The change in DSQ co-primary endpoint for the overall cohort showed a reduction from baseline of -17.4 HD and -11.9 LD vs. -14.6 for PBO (P=0.2372; Fig. B1), whereas the change in adolescents was -18.4 HD and -16.4 LD vs. -8.9 PBO (P=0.1316; Fig. B2). The most common adverse events (AEs) were infusion related reactions (38.5% HD, 25.8% LD, 12% PBO) and headache (6.6% HD, 8.6% LD, 6.5% PBO); there were 3 serious AEs (2 HD, 1 PBO).

Discussion: This phase 2/3 trial of lirentelimab met the histologic co-primary endpoint but did not meet the DSQ symptom co-primary endpoint, although in adolescents there was a trend in DSQ response over PBO. Lirentelimab was generally well-tolerated. This study included a broad range of patients with EoE, and identification of factors associated with symptoms and histologic response will improve our understanding of disease activity and help identify patients who may respond to biologic therapy.




Disclosures:


Evan Dellon, MD, MPH¹, Mirna Chehade, MD, MPH², Robert M. Genta, MD³, David A. Leiman, MD⁴, Kathryn A. Peterson, MD, MSCI⁵, Jonathan Spergel, MD, PhD⁶, Joshua Wechsler, MD, MS⁷, Enoch Bortey, PhD⁸, Alan T. Chang, BS⁸, Ikuo Hirano, MD, PhD⁹. D0201 - Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents With EoE, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.